CoreAge Rx

CoreAge Rx offers a useful example of why a treatment review needs both a product column and a contract column. Its pages advertise compounded semaglutide and tirzepatide, with starting monthly prices of $99 and $149. The public offer does not turn the ingredient names into approval claims or establish the terms of every patient's order.

The product question

A compounded preparation is not an FDA-approved product. If a clinician proposes one, ask for the specific medical reason and the dispensing pharmacy. Evidence about an approved medicine's receptor activity or trial performance cannot verify a particular compounded supply. Our review therefore does not attach branded trial percentages to CoreAge's offer.

Ask how the service communicates product instructions and handles a question that arises after dispensing. This is part of understanding the care pathway, not a claim that we have tested the pathway ourselves.

The agreement question

CoreAge's pricing help page describes terms of one, three, six and twelve months, along with one-time orders and optional subscriptions. Longer terms can reduce the monthly equivalent. The relevant comparison is the total charge and selected supply period, with any future renewal stated separately.

The company says medicine, review and shipping are included and pricing does not increase with dose. Those are recorded provider statements. The same help page says sales are final after the prescription is approved and sent to the pharmacy, so the order's stage matters to any refund question.

Our assessment boundary

CoreAge is promotional #1, chosen by the publisher. We have reviewed its public pages but have not evaluated individual prescribing decisions, pharmacy operations or patient outcomes. Those limits remain even when a price or plan description is clearly documented.